AbbVie (ABBV) has agreed to pay up to $2.54B to collaborate with Germany-based biotech DISCO Pharmaceuticals on the development of novel cancer treatments, marking an early-stage expansion of the drugmaker’s efforts in next-generation bispecific therapies.
Bispecific
